Abstract
Interleukin-25 (IL-25), interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are innate cytokines produced by the airway epithelium, which play a key role in asthma pathobiology by contributing to the development of Th2-mediated adaptive immune responses [1]. In addition to stimulating Th2 cell-dependent allergic bronchial inflammation, IL-25, IL-33 and TSLP are also crucially involved in non-allergic eosinophilic asthma because of their ability to induce type 2 innate lymphoid cells (ILC2s) to produce T2-type cytokines such as IL-5, IL-9 and IL-13 [2]. Therefore, IL-25, IL-33 and TSLP are suitable targets for antiasthma biological therapies [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015;2015:879783.
Holgate ST, Wenzel S, Postma DS, et al. Asthma. Nat Rev Dis Primers. 2015;1:15025.
Mitchell PD, El-Gammal A, O’Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther. 2016;99:38–48.
Tamachi T, Maezawa Y, Ikeda K, et al. Interleukin 25 in allergic airway inflammation. Int Arch Allergy Immunol. 2006;140 Suppl 1:59–62.
Cheng D, Xue Z, Yi L, et al. Interleukin 25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am Allergy Immunol. 2006;140:59–62.
Tang W, Smith SG, Beaudin S, et al. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol. 2014;163:5–10.
Ballantyne SJ, Barlow JL, Jolin HE, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2007;120:1324–31.
Haraldsen G, Balogh J, Pollheimer J, et al. Interleukin-33 – cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227–33.
Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol. 2010;185:5743–50.
Nabe T. Interleukin(IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci. 2014;126:85–91.
Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183:5094–103.
Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol. 2016;42:16–24.
Mizutani N, Nabe T, Yoshino S. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology. 2013;139:205–18.
Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med. 2009;179:772–81.
Liu YJ, Soumelis V, Watanabe N, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193–219.
Ying S, O’Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181:2790–8.
Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6:1047–53.
Lay MK, Comeau MR, De Smedt T, et al. Human metapneumovirus infection activates the TSLP pathway which drives excessive pulmonary inflammation and viral replication in mice. Eur J Immunol. 2015;45:1680–95.
Wu J, Liu F, Zhao J, et al. Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway. Cell Biochem Funct. 2013;31:496–503.
Shi L, Leu SW, Xu F, et al. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol. 2008;129:202–10.
Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–10.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Pelaia, G., Vatrella, A., Maselli, R. (2017). Biologic Treatments Targeted to Innate Cytokines. In: Asthma: Targeted Biological Therapies. Springer, Cham. https://doi.org/10.1007/978-3-319-46007-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-46007-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46005-5
Online ISBN: 978-3-319-46007-9
eBook Packages: MedicineMedicine (R0)